Sanofi has teamed up with US tech firm Evidation Health to tap into its behavioural data analysis platform, Real Life Study, for work that will be powered with data collected from wearables and mobile applications.
The three-year partnership aims to increase Sanofi’s understanding of disease burden and develop solutions from the data that will improve therapeutic outcomes.
Christine Lemke, co-founder and president of Evidation Health, said: “Consumers are sharing their digital footprint through wearables, sensors and apps, and we need to listen so we can better help them navigate their day-to-day health journey.”
According to a national survey conducted by Rock Health, 46% of US consumers were considered active digital health adopters, with 24% owning a wearable and 22% actively tracking at least one key health factor via a mobile application.
Digitally analysing patient behaviours can play a ‘significant’ role in patient outcomes and can even predict how likely it is for an individual to get ill, according to Evidation.
Heather Bell, senior vice president and global head of digital and analytics at Sanofi, said: “Working closely with Evidation and its distinctive analytics platform will help us better understand the factors that affect patient outcomes.
“We can then use those insights to support patients and healthcare professionals in managing disease and delivering the most value from our therapies.”
The duo previously worked together to identify behavioural markets that could improve treatment adherence and guide positive lifestyle change in patients with type 2 diabetes.
Lemke added: “By partnering with Sanofi’s innovative team, we have an opportunity to better manage population health in the digital era by illuminating underlying health behaviours in a privacy-safe and patient-permissioned way.”
